SCHEMBL3636992

SCHEMBL3636992

FC(F)(F)c1ccc(-c2n[nH]cc2CNc2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.44
MAPK14 Q16539 1/20 0.43
MAPT P10636 2/20 0.42
CACNA1H O95180 1/20 0.41
FFAR1 O14842 2/20 0.40
GHSR Q92847 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
GCGR P47871 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
TTBK1 Q5TCY1 1/20 0.38
BRD4 O60885 1/20 0.38
LTA4H P09960 1/20 0.38
EPHX2 P34913 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636635 0.90 GRK2 (0.47) CACNA1BMAPK14MAPTFFAR1MAOB
SCHEMBL3641215 0.89 MAPT (0.44) CACNA1BMAPTFFAR1GHSRGCGR
SCHEMBL3637490 0.87 CCNE1 (0.42) CACNA1BMAPTCCNE1CDK2TTBK1
SCHEMBL3637301 0.86 MAPT (0.48) CACNA1BMAPTFFAR1BRD4MEN1
SCHEMBL3635851 0.86 ERBB2 (0.47) MAPTFFAR1CCNE1CDK2
SCHEMBL3634547 0.84 CLK1 (0.46) MAPK14MAPTFFAR1GHSRCCNE1
SCHEMBL3640089 0.83 FRK (0.46) MAPTFFAR1GCGREPHX2RAB9A
SCHEMBL3636650 0.83 ERBB2 (0.43) MAPTGCGRCCNE1CDK2MEN1
SCHEMBL3637862 0.83 ERBB2 (0.43) MAPK14MAPTFFAR1CCNE1CDK2
SCHEMBL3637504 0.81 FRK (0.40) CACNA1BMAPTCACNA1HFFAR1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
CN-101687790-B Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) ABBVIE INC 2015-02-11 CN disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
CN-101687790-A Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2(MGLU2 receptor) ABBOTT GMBH & CO KG 2010-03-31 CN disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 CACNA1B 462/4885MAPK14 2225/4885MAPT 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.